WSI Achieves 40.4 Billion KRW in Sales Last Year, Up 31% Year-on-Year

WSI achieved significant external growth last year due to the strong performance of its existing core business and the reflection of subsidiary consolidated earnings.

WSI announced on the 24th that its consolidated sales last year reached 40.4 billion KRW, a 30.9% increase compared to the previous year. Operating profit during the same period rose by 15.3% to 3.9 billion KRW.

The substantial increase in sales last year was due to the stable growth of the existing pharmaceutical and medical device distribution business and the inclusion of subsidiary IntroBioPharma’s performance in the consolidated results. The core product, topical hemostatic agents, continued double-digit growth based on strong market dominance. Central venous catheters (CVC) and peripherally inserted central catheters (PICC), launched in cooperation with the UK-based company KIMAL, also successfully established themselves in the market.

The performance of IntroBioPharma, a specialty pharmaceutical company focusing on circulatory and metabolic diseases, was reflected in the consolidated results from the second half of the year, driving additional growth. This year, further expansion is expected through strengthened sales utilizing WSI’s nationwide network of over 400 hospitals and clinics, as well as the launch of new generic drugs such as antiepileptics and treatments for hypertension and hyperlipidemia.

A WSI representative stated, "We recorded strong external growth with the stable growth of the topical hemostatic agent business and the launch of new medical devices. In particular, from the second half of the year, the inclusion of subsidiary IntroBioPharma’s performance in the consolidated results enabled additional external and earnings improvements."

They added, "This year, with the full-year reflection of IntroBioPharma’s performance, even higher external growth and earnings improvement are expected, and it will be a year to achieve visible results in the next-generation growth engine, the medical robot business."

Meanwhile, WSI’s subsidiary EasyMediBot has completed the prototype development of 'Ubot,' a robot that supports laparoscopic surgery and drug injection. The application of Ubot can shorten surgery time, improve diagnostic accuracy, and increase surgical success rates. The company plans to complete product approval from the Ministry of Food and Drug Safety and proceed with commercialization within this year.